Authors
Latest:
Making Intervention Accessible for All Li-Fraumeni Syndrome PopulationsMichael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.
Latest:
Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic CancerSuneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.
Latest:
‘Future Is Bright’ With Bispecifics for Relapsed/Refractory MyelomaAn expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
Latest:
Future Perspectives and Unmet Needs in Multiple MyelomaThe expert panel concludes their discussion by examining the unmet needs and future for the treatment landscape in multiple myeloma.
Latest:
Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-USIbrahim Halil Sahin, MD, and colleagues, explore, the CIRCULATE-US (NRG-GI008; NCT05174169) investigating postoperative ctDNA dynamics in early-stage colon cancer for treatment selection.
Latest:
Face-Off: Award Presentations and Event ConclusionJudy concludes the event and presents the awards.
Latest:
CLM in GALAXY: MRD Predicts Adjuvant Therapy Benefit and PrognosisPanelists discuss how minimal residual disease (MRD) detection in patients with colorectal liver metastases (CLM) in the GALAXY study predicts both the benefit of adjuvant therapy and overall prognosis, potentially guiding more personalized treatment decisions.
Latest:
Matthew Krebs, MB, PhD, Reviews the Next Steps for Subcutaneous Amivantamab in Solid TumorsMatthew Krebs, MB, PhD, spoke about how subcutaneous amivantamab can best be utilized in future clinical trials.
Latest:
Closing Thoughts, Future Perspectives, and Key Takeaways in the Treatment of Epithelioid SarcomaPanelists discuss how early recognition, accurate diagnosis through histopathology and molecular testing, and multidisciplinary collaboration are critical for optimizing treatment strategies in epithelioid sarcoma (ES), while future research into targeted therapies holds promise for improving outcomes, especially in advanced cases.
Latest:
Management of Testicular Germ Cell Tumor With Somatic-Type MalignancyIn this installment of Clinical Quandaries, Bendu Konneh, BS, and colleagues present a case of a 21-year-old male with a 4-month history of progressive swelling in the right testicle.
Latest:
Lumpectomy Yields Clinically ‘Acceptably Low’ Recurrence Rates in Breast Cancer SubtypeJudy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota details the efficacy of breast-conserving surgery in patients with multiple ipsilateral breast cancer.
Latest:
Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous RituximabRituximab-subcutaneously is associated with significantly reduced chair time vs rituximab-intravenously in a US oncology setting. Widespread adoption would be expected to improve practice efficiency and patient access to care, and to reduce health care resource burden.
Latest:
Optimizing Surgery With New AI Technologies in Breast and Ovarian Cancer“Frozen section is destructive. It ruins the tissue, it consumes the tissue, and it affects downstream molecular analysis,” according to Farzad Fereidouni, PhD.
Latest:
Future Directions in the Treatment of Multiple MyelomaDrs Richter and Fanning discuss next steps and future directions in the management of patients with relapsed/refractory multiple myeloma.
Latest:
Unusual Initial Presentation of Hepatocellular Carcinoma as a Clavicular Head MassRohit Gupta, MD, et al review a case study of a 70-year-old man who presented with a head mass, and the final diagnosis was hepatocellular carcinoma.
Latest:
Educating Patients and Caregivers on Infection Risks of Anti-BCMA Bispecific Antibodies in MM TreatmentThe panel discusses how to educate patients and caregivers on infections risks when receiving an anti-BCMA bispecific antibody.
Latest:
Oncology Peer Review On-The-Go: Current Treatments in Peripheral T-cell LymphomaRobert Stuver, MD, and Zachary D. Epstein-Peterson, MD, spoke with CancerNetwork® about a review article on the treatment of peripheral T-cell lymphoma published in the journal ONCOLOGY®.
Latest:
Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-USIbrahim Halil Sahin, MD, and colleagues, explore, the CIRCULATE-US (NRG-GI008; NCT05174169) investigating postoperative ctDNA dynamics in early-stage colon cancer for treatment selection.
Latest:
The Future of DLBCL: Innovations in Therapy and Patient CarePanelists discuss how the treatment landscape for diffuse large B-cell lymphoma (DLBCL) is poised for transformation as novel chimeric antigen receptor T-cell approaches integrate with existing therapies, enhancing efficacy and durability. Insights from Tandem 2025 highlight advancements in cellular therapy, including combinatorial strategies and next-generation chimeric antigen receptor T-cell designs, driving optimism for improved patient outcomes.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Kathryn Maples, PharmD, BCOP, on Key Considerations for Belantamab Mafodotin Administration in Multiple MyelomaA clinical pharmacy specialist discusses what’s needed to get the REMS program set up and touches on reimbursement considerations for the administration of belantamab mafodotin in patients with multiple myeloma.
